BRIEF published on 07/11/2024 at 07:10, 2 years ago Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business Financial Results Clinical Trial Heidelberg Pharma HDP-101 Multiple Myeloma
PRESS RELEASE published on 07/11/2024 at 07:05, 2 years ago Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business Heidelberg Pharma AG reports positive preliminary efficacy data for HDP-101 in multiple myeloma clinical trial. Key events include AACR Meeting presentation & FDA Orphan Drug Designation Clinical Trial HDP-101 Heidelberg Pharma AG AACR Meeting FDA Orphan Drug Designation
BRIEF published on 06/21/2024 at 11:21, 2 years ago Heidelberg Pharma Reports on the Results of the Annual General Meeting 2024 Shareholders Financial News Resolutions Heidelberg Pharma AGM 2024
PRESS RELEASE published on 06/21/2024 at 11:16, 2 years ago Heidelberg Pharma reports on the results of the Annual General Meeting 2024 Heidelberg Pharma AG reports on the results of the Annual General Meeting 2024, including approval of resolutions and shareholder attendance Shareholders Voting Results Annual General Meeting 2024 Cancer Therapy Heidelberg Pharma AG
BRIEF published on 06/18/2024 at 13:52, 2 years ago Heidelberg Pharma AG Announces Updated Guidance for 2024 Revenue Forecast Financial Guidance Biotech Heidelberg Pharma AG Operating Expenses
PRESS RELEASE published on 06/18/2024 at 13:47, 2 years ago EQS-Adhoc: Heidelberg Pharma AG announces updated guidance Heidelberg Pharma AG updates guidance for fiscal year 2024, lowering sales expectations due to delays and adjusting operating expenses. Financing secured until mid-2025 with potential expansion until end of 2026 Financial Year 2024 Heidelberg Pharma AG Operating Expenses Sales Expectations Updated Guidance
BRIEF published on 05/23/2024 at 09:17, 2 years 1 month ago Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024 Cancer Treatment Conférences Heidelberg Pharma HDP-101 ADCs
PRESS RELEASE published on 05/23/2024 at 09:12, 2 years 1 month ago Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024 Heidelberg Pharma AG to participate and present at leading scientific conferences in May and June 2024, showcasing innovative ADC technology platforms for cancer treatment Cancer Treatment ADC Technology Heidelberg Pharma AG Scientific Conferences Clinical Stage Biotech
BRIEF published on 04/25/2024 at 07:26, 2 years 2 months ago Heidelberg Pharma AG Reports on Q1 2024 Financials and Operational Progress Financial Performance CEO Appointment Heidelberg Pharma AG HDP-101 Clinical Trial ADC Pipeline Development
PRESS RELEASE published on 04/25/2024 at 07:21, 2 years 2 months ago Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024 Heidelberg Pharma AG reports on its interim management statement for the first three months of 2024, including first efficacy data from a clinical trial and successful financing activities Clinical Trial Heidelberg Pharma AG ADC Pipeline Interim Statement Financing Activities
Published on 07/15/2026 at 14:30, 2 hours 27 minutes ago Avant Brands Reports Q2 2026 Results Highlighted by 34% Growth in Recreational Revenue
Published on 07/15/2026 at 14:30, 2 hours 27 minutes ago Innodata to Report Second Quarter 2026 Results
Published on 07/15/2026 at 14:30, 2 hours 27 minutes ago Fermi Outlines Strategic Rationale for Upsized $431 Million Convertible Notes Offering
Published on 07/15/2026 at 14:30, 2 hours 27 minutes ago Sekur Private Data Launches SekurOne with Encrypted Voice for All Devices
Published on 07/15/2026 at 14:00, 2 hours 57 minutes ago GameSquare Provides Update to Capital Allocation Strategy
Published on 07/15/2026 at 15:20, 1 hour 37 minutes ago Seegene: "Virus-Only Testing May Miss Pneumonia-associated Bacterial Respiratory Pathogens" Calls for a Shift to Comprehensive Syndromic PCR Testing
Published on 07/15/2026 at 15:10, 1 hour 47 minutes ago Xryma Plc Announces Approval and Publication of its Prospectus for Admission to Trading on Euronext Paris
Published on 07/15/2026 at 15:05, 1 hour 52 minutes ago Precisely Appoints New Chief Revenue Officer and Chief Business Officer as Market Demand for Agentic-Ready Data Intensifies
Published on 07/15/2026 at 15:05, 1 hour 52 minutes ago Maya HTT Welcomes Friendship Systems and CAESES to Expand Simulation-Driven Design and Optimization Software Portfolio
Published on 07/13/2026 at 18:00, 1 day 22 hours ago PR Icade - Icade regains full ownership of the Eqho Tower in La Défense
Published on 07/13/2026 at 07:30, 2 days 9 hours ago Disclosure of transactions in own shares from July 6 to July 10, 2026
Published on 07/10/2026 at 18:00, 4 days 22 hours ago Half-year liquidity contract statement for CEGEDIM
